Mapi Pharma Ltd., a fully integrated, late clinical stage biopharmaceutical company, is dedicating capacity at its manufacturing facility to support the global effort to provide COVID-19 vaccination to Israel, the EU and globally.
 
Mapi Pharma has production facilities for sterile injectable Finished Dosage Forms (FDF). Its large GMP approved facility is audited by the Israeli Ministry of Health. Israeli Ministry of Health approvals are mutually recognized by the EU, with Israeli manufacturers being exempt from the requirement to perform laboratory tests on shipments from Israel to Europe. Furthermore, results of audits performed by the institute for auditing and standards of medical products within the Ministry of Health are also recognized by the European countries.
 
Mapi is currently expanding its Jerusalem Fill & Finish facility. Over $100 million has been invested in the facility which was built to supply J&J’s own needs of sterile products. Mapi is now adding a new line for sterile filling and finishing of liquids and powders for injections to the facility. This will support the global effort to bring a COVID-19 vaccine, once approved, to Israeli, EU citizens and potentially from many other countries.
 
Ehud Marom, chairman and chief executive officer of Mapi, said, “We are making available our production capacity, as well as our cold-chain and storage capacities, for the delivery of vaccines to Israeli and EU. The global supply chain of vaccinations is currently limited and requires agility to enable the supply of vaccines on a broad scale. By making our manufacturing capacity available, we hope to assist in the quick deployment of vaccines once they are approved by the heath authorities. We are in communications with the major vaccination developers and governments to join forces in the fight against this dangerous virus.”



Source link